Literature DB >> 27591497

Liposarcoma: Multimodality Management and Future Targeted Therapies.

Aimee M Crago1, Mark A Dickson2.   

Abstract

There are 3 biologic groups of liposarcoma: well-differentiated and dedifferentiated liposarcoma, myxoid/round cell liposarcoma, and pleomorphic liposarcoma. In all 3 groups, complete surgical resection is central in treatment aimed at cure and is based on grade. Radiation can reduce risk of local recurrence in high-grade lesions or minimize surgical morbidity in the myxoid/round cell liposarcoma group. The groups differ in chemosensitivity, so adjuvant chemotherapy is selectively used in histologies with metastatic potential but not in the resistant subtype dedifferentiated liposarcoma. Improved understanding of the genetic aberrations that lead to liposarcoma initiation is allowing for the rapid development of targeted therapies for liposarcoma.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CDK4; FUS-CHOP; Liposarcoma; MDM2; Myxoid liposarcoma; Pleomorphic liposarcoma; Sarcoma; Trabectedin

Mesh:

Year:  2016        PMID: 27591497      PMCID: PMC5010855          DOI: 10.1016/j.soc.2016.05.007

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  57 in total

1.  A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation.

Authors:  Oren Cahlon; Murray F Brennan; Xiaoyu Jia; Li-Xuan Qin; Samuel Singer; Kaled M Alektiar
Journal:  Ann Surg       Date:  2012-02       Impact factor: 12.969

2.  Surgery in retroperitoneal soft tissue sarcoma: a call for a consensus between Europe and North America.

Authors:  Alessandro Gronchi; Raphael Pollock
Journal:  Ann Surg Oncol       Date:  2011-08       Impact factor: 5.344

3.  Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

Authors:  Xavier García-Del-Muro; Antonio López-Pousa; Joan Maurel; Javier Martín; Javier Martínez-Trufero; Antonio Casado; Auxiliadora Gómez-España; Joaquín Fra; Josefina Cruz; Andrés Poveda; Andrés Meana; Carlos Pericay; Ricardo Cubedo; Jordi Rubió; Ana De Juan; Nuria Laínez; Juan Antonio Carrasco; Raquel de Andrés; José M Buesa
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

4.  Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas.

Authors:  Barry S Taylor; Penelope L DeCarolis; Christina V Angeles; Fabienne Brenet; Nikolaus Schultz; Cristina R Antonescu; Joseph M Scandura; Chris Sander; Agnes J Viale; Nicholas D Socci; Samuel Singer
Journal:  Cancer Discov       Date:  2011-12       Impact factor: 39.397

5.  The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.

Authors:  Fritz C Eilber; Frederick R Eilber; Jeffery Eckardt; Gerald Rosen; Elyn Riedel; Robert G Maki; Murray F Brennan; Samuel Singer
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

6.  Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control.

Authors:  Sylvie Bonvalot; Michel Rivoire; Marine Castaing; Eberhard Stoeckle; Axel Le Cesne; Jean Yves Blay; Agnès Laplanche
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

7.  MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation.

Authors:  Yetao Jin; Hunjoo Lee; Shelya X Zeng; Mu-Shui Dai; Hua Lu
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

8.  Liposarcoma of the extremities: MR and CT findings in the histologic subtypes.

Authors:  J S Jelinek; M J Kransdorf; B M Shmookler; A J Aboulafia; M M Malawer
Journal:  Radiology       Date:  1993-02       Impact factor: 11.105

9.  Atypical lipomatous tumor/well-differentiated liposarcoma of the extremity and trunk wall: importance of histological subtype with treatment recommendations.

Authors:  David A Kooby; Cristina R Antonescu; Murray F Brennan; Samuel Singer
Journal:  Ann Surg Oncol       Date:  2004-01       Impact factor: 5.344

10.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Authors:  Robert G Maki; J Kyle Wathen; Shreyaskumar R Patel; Dennis A Priebat; Scott H Okuno; Brian Samuels; Michael Fanucchi; David C Harmon; Scott M Schuetze; Denise Reinke; Peter F Thall; Robert S Benjamin; Laurence H Baker; Martee L Hensley
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544

View more
  36 in total

1.  Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma.

Authors:  Lee S Gottesdiener; Shannon O'Connor; Klaus J Busam; Helen Won; David B Solit; David M Hyman; Alexander N Shoushtari
Journal:  Clin Cancer Res       Date:  2018-08-09       Impact factor: 12.531

2.  Quantification of fat content in lipid-rich myxoid liposarcomas with MRI: a single-center experience with survival analysis.

Authors:  Gokhan Kuyumcu; Brian P Rubin; Jennifer Bullen; Hakan Ilaslan
Journal:  Skeletal Radiol       Date:  2018-06-08       Impact factor: 2.199

Review 3.  Dedifferentiated Liposarcoma: Systemic Therapy Options.

Authors:  Zhubin Gahvari; Amanda Parkes
Journal:  Curr Treat Options Oncol       Date:  2020-02-05

Review 4.  Magnetic resonance imaging of trunk and extremity myxoid liposarcoma: diagnosis, staging, and response to treatment.

Authors:  Asif Saifuddin; Vanghelita Andrei; Ramanan Rajakulasingam; Ines Oliveira; Beatrice Seddon
Journal:  Skeletal Radiol       Date:  2021-04-01       Impact factor: 2.199

5.  Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.

Authors:  Sandhya Noronha; Lauren A C Alt; Taylor E Scimeca; Omran Zarou; Justyna Obrzut; Brian Zanotti; Elizabeth A Hayward; Akhil Pillai; Shubha Mathur; Joseph Rojas; Ribhi Salamah; Nalini Chandar; Michael J Fay
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-12-01       Impact factor: 2.416

Review 6.  Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters.

Authors:  Sarah Abaricia; Angela C Hirbe
Journal:  Curr Treat Options Oncol       Date:  2018-10-25

7.  Lipoblastomas and liposarcomas in paediatric patients: A case series.

Authors:  Joyce J L H McRae; Asra Hashmi; Andrei Radulescu; Cody S Carter; Faraz A Khan
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

Review 8.  Systematic review of giant gastric lipomas reported since 1980 and report of two new cases in a review of 117110 esophagogastroduodenoscopies.

Authors:  Mitchell S Cappell; Charlton E Stevens; Mitual Amin
Journal:  World J Gastroenterol       Date:  2017-08-14       Impact factor: 5.742

9.  Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis.

Authors:  Kamil M Amer; Dominick V Congiusta; Jennifer E Thomson; Samer Elsamna; Iftikhar Chaudhry; Anthony Bozzo; Rami Amer; Brianna Siracuse; Michelle Ghert; Kathleen S Beebe
Journal:  J Clin Orthop Trauma       Date:  2020-04-18

Review 10.  Update of pediatric soft tissue tumors with review of conventional MRI appearance-part 1: tumor-like lesions, adipocytic tumors, fibroblastic and myofibroblastic tumors, and perivascular tumors.

Authors:  Jack Porrino; Khalid Al-Dasuqi; Lina Irshaid; Annie Wang; Kimia Kani; Andrew Haims; Ezekiel Maloney
Journal:  Skeletal Radiol       Date:  2021-06-30       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.